Please login to the form below
Fycompa
This page shows the latest Fycompa news and features for those working in and with pharma, biotech and healthcare.
Germany planning to table pricing reforms 'by the summer'
Eisai did likewise for its epilepsy treatment Fycompa (perampanel).
Latest news
-
Eisai establishes neuroscience unit in Belgium and Luxembourg
The new unit will market the company's epilepsy drug Fycompa (perampanel), which it has been giving a rolling launch across the region. ... Fycompa indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised
-
Eisai opens first office in Australia
New Melbourne base to support marketing of Halaven and Fycompa. Japan-based pharma firm Eisai has extended its global expansion with a new office in Melbourne, Australia. ... Fycompa is the first in a new class of treatment for partial onset seizures,
-
Eisai "speechless" as G-BA denies price premium for Fycompa
But company has better news on cancer drug Halaven. . Eisai's efforts to secure favourable pricing for its epilepsy drug Fycompa in Germany have hit the buffers once again. ... The German Federal Joint Committee (G-BA) has concluded once again that
-
Eisai backs competition to find star of epilepsy comic book
Epilepsy is a relative new area of focus for Eisai, whose treatment options include Fycompa (perampanel), which was launched in Europe in 2012.
-
Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug
Eisai has issued a damning statement criticising Germany's healthcare watchdog IQWIG for not backing epilepsy drug Fycompa. ... IQWIG's recommendation will now be considered by the G-BA, which is expected to published a decision on Fycompa's use in
Eisai establishes neuroscience unit in Belgium and Luxembourg
Eisai backs competition to find star of epilepsy comic book
Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug
More from news
Approximately 10 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
by adding a new solid dose global manufacturing line for its anti-epileptic medicine Fycompa. ... Fycompa was the first Eisai-developed epilepsy drug and it's “a drug we can really differentiate”, says Hendler.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Novo Nordisk settles US insulin pricing dispute for $100m
- Lynparza significantly delays disease progression as first-line treatment in prostate cancer
- Mylan completes acquisition of Merck's generic unit
- Pfizer starts RSV trial ahead of winter season
- WHO has recommended GSK’s malaria vaccine for children
- World Mental Health Day is on 10 October
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
